Patents by Inventor William C. Shakespeare

William C. Shakespeare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20240317731
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having a structure according to Formula (I): wherein X1, R1, R2, m, and n are described herein.
    Type: Application
    Filed: January 5, 2022
    Publication date: September 26, 2024
    Applicant: Theseus Pharmaceuticals, Inc.
    Inventors: David C. DALGARNO, Wei-Sheng HUANG, William C. SHAKESPEARE
  • AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20240208960
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: July 28, 2023
    Publication date: June 27, 2024
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • MACROCYCLIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20240199614
    Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: March 25, 2022
    Publication date: June 20, 2024
    Applicant: Theseus Pharmaceuticals, Inc.
    Inventors: Wei-Sheng HUANG, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240150375
    Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: November 10, 2023
    Publication date: May 9, 2024
    Applicant: Theseus Pharmaceuticals, Inc.
    Inventors: Wei-Sheng HUANG, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
  • Heteroaryl compounds for kinase inhibition
    Patent number: 11958850
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 16, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Aminothiazole compounds as c-Kit inhibitors
    Patent number: 11753404
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: September 12, 2023
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20230148005
    Abstract: Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: February 18, 2021
    Publication date: May 11, 2023
    Inventors: Wei-Sheng Huang, William C. SHAKESPEARE, Charles J. EYERMANN, David C. DALGARNO
  • Heteroaryl Compounds For Kinase Inhibition
    Publication number: 20230102829
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 30, 2023
    Inventors: WEI-SHENG HUANG, YONGJIN GONG, FENG LI, NICHOLAS E. BENCIVENGA, DAVID C. DALGARNO, ANNA KOHLMANN, WILLIAM C. SHAKESPEARE, RANNY M. THOMAS, XIAOTIAN ZHU, ANGELA V. WEST, WILLMEN YOUNGSAYE, YUN ZHANG, TIANJUN ZHOU
  • SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220081440
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: October 12, 2021
    Publication date: March 17, 2022
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20220064144
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 3, 2022
    Inventors: Nicholas E. BENCIVENGA, David C. DALGARNO, Joseph M. GOZGIT, Wei-Sheng HUANG, Anna KOHLMANN, Feng LI, Jiwei QI, William C. SHAKESPEARE, Ranny M. THOMAS, Yihan WANG, Yun ZHANG, Xiaotian ZHU
  • AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20220033392
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: April 9, 2021
    Publication date: February 3, 2022
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20210323976
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: October 21, 2021
    Inventors: Wei-Sheng Huang, Tianjun Zhou, Willmen W. Youngsaye, William C. Shakespeare, Alexey V. Ishchenko, David C. Dalgarno
  • Benzimidazole compounds as c-Kit inhibitors
    Patent number: 11117883
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
  • Aminothiazole compounds as c-Kit inhibitors
    Patent number: 11001580
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 11, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20200317705
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: November 1, 2019
    Publication date: October 8, 2020
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Bicyclic Heteroaryl Compounds
    Publication number: 20200231588
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 23, 2020
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20200048288
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: April 19, 2019
    Publication date: February 13, 2020
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20200039958
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: February 6, 2020
    Inventors: Nicholas E. BENCIVENGA, David C. DALGARNO, Joseph M. GOZGIT, Wei-Sheng HUANG, Anna KOHLMANN, Feng LI, Jiwei QI, William C. SHAKESPEARE, Ranny M. THOMAS, Yihan WANG, Yun ZHANG, Xiaotian ZHU
  • AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS
    Publication number: 20190352298
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other -threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: November 21, 2019
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20190218212
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 18, 2019
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou